Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”

Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.

New York, NY - June 22, 2022: Dr. Leonard Schleifer attends Governor Kathy Hochul announcement during groundbreaking for Regeneron facilities at company campus in Tarrytown
CEO Leonard Schleifer at a June event on Regeneron's Tarrytown, NY campus • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer weighed in on the Federal Trade Commission’s attempt to block Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc, taking the stage at the Financial Times US Pharma and Biotech Summit on 16 May moments after the FTC announced it would seek to block the merger on the basis of Amgen’s rebating practices to support the federal agency’s move. 

Schleifer’s opinion of the FTC decision may be unexpected coming from a top pharma CEO, something not uncommon during the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.